- Home
- NEA vs NRIX Comparison
NEA vs NRIX Comparison
Compare NEA & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NEA | NRIX |
|---|---|---|
| Founded | N/A | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 2.6B |
| IPO Year | 2002 | 2020 |
Fundamental Metrics
Financial Performance| Metric | NEA | NRIX |
|---|---|---|
| Price | $10.34 | $26.95 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 14 |
| Target Price | N/A | ★ $34.50 |
| AVG Volume (30 Days) | ★ 2.3M | 2.1M |
| Earning Date | 01-01-0001 | 10-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 3.26 |
| Revenue | N/A | ★ $76,987,000.00 |
| Revenue This Year | N/A | $786.93 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $8.32 |
| Revenue Growth | N/A | ★ 99.31 |
| 52 Week Low | $9.53 | $11.67 |
| 52 Week High | $11.90 | $28.23 |
Technical Indicators
Market Signals| Indicator | NEA | NRIX |
|---|---|---|
| Relative Strength Index (RSI) | 56.07 | 63.98 |
| Support Level | $9.72 | $24.61 |
| Resistance Level | $11.72 | $28.23 |
| Average True Range (ATR) | 0.16 | 1.28 |
| MACD | 0.07 | 0.39 |
| Stochastic Oscillator | 91.35 | 81.84 |
Price Performance
Historical ComparisonAbout NEA Nuveen AMT-Free Quality Municipal Income Fund of Beneficial Interest Par Value $.01
Nuveen AMT-Free Municipal Income Fund is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax and the alternative minimum tax applicable to individuals, by investing in an actively managed portfolio of tax-exempt municipal securities. The company invest in Transportation, Utilities, Healthcare, Education and Civics, and other sectors, with maximum investment in Transportation.
About NRIX Nurix Therapeutics Inc.
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.